Compare KFFB & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KFFB | RNTX |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.2M | 42.9M |
| IPO Year | 2004 | N/A |
| Metric | KFFB | RNTX |
|---|---|---|
| Price | $4.51 | $1.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 1.5K | ★ 118.2K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 109.52 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $15,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $56.38 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.96 | $1.02 |
| 52 Week High | $4.98 | $2.22 |
| Indicator | KFFB | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.36 | 68.31 |
| Support Level | $4.48 | $1.08 |
| Resistance Level | $4.89 | $2.18 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 71.95 | 89.83 |
Kentucky First Federal Bancorp is a holding company. The company, through its subsidiaries, is engaged mainly in the business of accepting deposits from the general public and using such funds to originate loans secured by first mortgages on owner-occupied, residential real estate and other loans secured by real estate. Its primary products and services include Residential mortgage loans, Multi-family loans, Construction loans, and types of deposits etc. The company mainly operates in Perry, Franklin, Boyle, and Garrard and surrounding counties in Kentucky, USA.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.